Getinge AB ser. B(0GZV)
SEK --+0.00%
Reward56Moderate
Risk22Low
📊75%Data
2.1% dividend yield · Revenue down 11% YoY
0GZV
+0.0 · +0.00%
SEK · LSE
Getinge AB ser. B |
Defensive Anchor
Market Cap:62.11Bn
ℹ️
Reward Rating
56
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
22
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0GZV to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Getinge AB ser. B?

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally.

0GZV · Verdict

Solid reward · low risk

0GZV scores well on balance sheet and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

0GZV · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet89/100

    Top decile vs peers

  • Cash flow87/100

    11% net margin

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Getinge AB ser. B?

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. The company is listed on the LSE in UK, with a market capitalisation of 62.11B, and a P/E ratio of 0.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap62.11B
P/E Ratio0.217
Dividend Yield2.09%
52 Week High224.5828
52 Week Low172.0728
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding272M
No. of Employees11,754
IndustryN/A
ExchangeLSE
Beta0.857
CurrencySEK